NOVA SCOTIA PROVINCIAL PHARMACARE PROGRAMS

Request for Insured Coverage of Agents for Attention Deficit Hyperactivity Disorder

PATIENT INFORMATION					
PATIENT SURNAME	PATIENT GIVEN NAME		HEALTH CARD NUMBER		DATE OF BIRTH
PATIENT ADDRESS					
TATIENT ADDICES					
REQUESTED MEDICATION					
☐ Methylphenidate (Foquest)* Dose:		Methylphenidate (Biphentin) and generic brands* Dose: imum dose reimbursed is 80 mg daily.)		Lisdexamfetamine Dimesylate (Vyvanse)	
(The maximum dose reimbursed is 100 mg daily.)	Dose:			Dose:(The maximum dose reimbursed is 60 mg daily.)	
			(The maximum deed formbareed to do mig daily.)		
METHYLPHENIDATE					
Methylphenidate*:					
1.) For the treatment of patients with attention deficit hyperactivity disorder who have tried other forms of extended-release methylphenidate with unsatisfactory results. (Please provide details below)					
2.) Medication trial:					
Extended-release methylphenidate: Please specify: Outcome:					
*Please refer to the Nova Scotia Formulary for a list of full-benefit methylphenidate products					
LISDEXAMFETAMINE DIMESYLATE					
Lisdexamfetamine Dimesylate:					
1.) Tor treatment of patients with attention deficit hyperactivity disorder who have tried extended-release methylphenidate, dexamphetamine or mixed salts amphetamine with unsatisfactory results. (Please provide details below)					
2.) Medication trial:					
Extended-release methylphenidate: Please specify:			(Outcome:	
Dexamphetamine: Please specify: Outcome:					
Mixed salts amphetamine: Please specify:Outcome:					
Additional Comments (if applicable):					
PRESCRIBER NAME & ADDRESS:					
_	LICENCE #	PRESCRIBER SIGNATURE DATE			

If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026

Please Return Form To: Nova Scotia Pharmacare Programs

P.O. Box 500, Halifax, NS B3J 2S1; Fax: (902) 496-4440

